查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571424

儿科癌症生物标记市场规模、份额、趋势分析报告：按适应症、按生物标记、按最终用途、细分市场预测，2024-2030 年

Pediatric Cancer Biomarkers Market Size, Share & Trends Analysis Report By Indication (Leukemia, Neuroblastoma, CNS Tumors, Lymphoma), By Biomarker (Alpha-fetoprotein, Neuron-specific enolase), By End Use, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

小儿癌症生物标记市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球儿科癌症生物标记市场规模将达到14.5亿美元，2024年至2030年复合年增长率为8.5%。

全球儿童癌症患者数量的增加是市场扩张的主要驱动力。根据 NIH 2023 年 2 月的报告，全球整体每年约有 40 万名 0-19 岁的儿童和青少年被诊断出罹患癌症。儿童癌症与成人癌症不同，白血病是最常见的癌症，其次是中枢神经系统 (CNS) 肿瘤和淋巴瘤。据各医疗机构称，儿童癌症比成人癌症更为​​罕见，但随着诊断技术的进步和认识的提高，被诊断出的机会正在增加。

目前正在进行大量研究工作，以发现新的生物标记，以促进儿童癌症的早期检测和治疗。例如，2024 年 6 月，费城儿童医院 (CHOP) 的研究人员宣布发现了一种新的基于免疫的生物标记。这种有前途的生物标记可能会彻底改变早期检测方法，有可能在卵巢癌通常变得明显之前两到四年检测出来。这些突破对于改善儿科肿瘤学的结果和存活率至关重要。随着研究不断产生创新的生物标誌物，市场正在扩大，对开发先进诊断工具的投资和关注也增加。这项进步不仅支持更早、更准确的诊断，而且还推动了整个儿科癌症生物标记市场的成长。

此外，学术机构、研究机构和製药公司之间的合作正在推动儿科癌症生物标记市场的创新。合作和伙伴关係透过共用专业知识和资源促进新生物标誌物的开发和检验。例如，2022 年 2 月，Lantern Pharma 宣布透过与德克萨斯大学健康科学中心的 Greehey 儿童癌症研究所合作，进一步扩展到儿科癌症领域。研究和官民合作关係将加速先进生物标记的发现和商业化。这些伙伴关係关係透过提高研发过程的效率以及更快、更有效地将新生物标记推向市场来促进市场成长。

此外，医疗保健基础设施的扩张和改善，特别是在新兴市场，正在推动儿科癌症生物标记市场的成长。随着各个地区的医疗保健系统的发展和现代化，先进诊断技术和生物标记测试的机会正在增加。改善的医疗设施和服务将使儿童癌症生物标记被广泛采用，从而提高诊断准确性和治疗效果。

儿科癌症生物标记市场报告亮点

  • 根据统计，白血病领域占最大，2023年将达40.8%。
  • 从生物标记来看，CD19、CD20和CD22片段在2023年占据最大份额，为29.7%，因为它们在血癌的诊断和标靶化中发挥重要作用。 CAR-T 细胞疗法等标靶治疗的进步利用这些生物标记来提高治疗效果和患者预后。精准医学应用的不断扩大对市场扩张做出了重大贡献。
  • 以最终用途计算，在投资增加和政府支持的推动下，到 2023 年，医院部门将占据最大份额，达到 40.5%。医院正在实施先进的生物标记技术，以提高儿童癌症的诊断准确性和个人化治疗。为研发提供资金以及引入创新诊断的激励措施等政府措施正在支持市场扩张。
  • 由于先进的研究、不断增加的癌症发病率以及对医疗基础设施的大量投资，北美儿科癌症生物标记市场在全球整体市场中占据主导地位，到 2023 年将占 43.8% 的销售份额。诊断技术的增强和对个人化医疗的关注正在推动市场扩张，以及对儿童癌症研究和治疗的大量资金和政府支持。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章儿科癌症生物标记市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 小儿癌症生物标记市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章儿科癌症生物标记市场：适应症估计和趋势分析

  • 细分仪表板
  • 小儿癌症生物标记市场：适应症变异分析
  • 小儿癌症生物标记市场：按适应症分類的前景
  • 2018-2030年市场规模、预测及趋势分析
  • 白血病
  • 神经母细胞瘤
  • 中枢神经系统肿瘤
  • 淋巴瘤
  • 其他的

第五章儿科癌症生物标记市场：生物标记估计和趋势分析

  • 细分仪表板
  • 小儿癌症生物标记市场：生物标记波动分析
  • 小儿癌症生物标记市场：生物标记展望
  • 2018-2030年市场规模、预测及趋势分析
  • 胎儿球蛋白(AFP)
  • 神经元特异性烯醇化酶 (NSE)
  • CD19、CD20、CD22
  • ALK（间变性淋巴瘤受体蛋白酪氨酸激酶基因）
  • 其他的

第六章儿科癌症生物标记市场：最终用途估计和趋势分析

  • 细分仪表板
  • 儿科癌症生物标记市场：最终用途变异分析
  • 小儿癌症生物标记市场：依最终用途分類的前景
  • 2018-2030年市场规模、预测及趋势分析
  • 医院
  • 诊断实验室
  • 肿瘤中心
  • 调查机构

第七章小儿癌症生物标记市场：区域估计和趋势分析

  • 区域仪表板
  • 2018-2030年市场规模、预测趋势分析
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 市场参与企业分类
  • 主要市场参与企业的最新趋势和影响分析
  • 策略规划
  • 主要企业简介
    • F. Hoffmann-La Roche Ltd
    • Abbott
    • Siemens Healthineers
    • Thermo Fisher Scientific
    • QIAGEN
    • Myriad Genetics
    • Beckman Coulter
    • Bio-Rad Laboratories
    • Agilent Technologies
    • BIOMERIEUX
    • RayBiotech, Inc
    • Randox Laboratories Ltd.
Product Code: GVR-4-68040-440-6

Pediatric Cancer Biomarkers Market Growth & Trends:

The global pediatric cancer biomarkers market size is anticipated to reach USD 1.45 billion by 2030 and is projected to grow at a CAGR 8.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rise in the number of pediatric cancer cases globally is a major driver for market expansion. According to a February 2023 NIH report, approximately 400,000 children and adolescents aged 0-19 are diagnosed with cancer globally each year. Pediatric cancers are distinct from those in adults, with the most prevalent types being leukemias, followed by central nervous system (CNS) tumors and lymphomas. According to various health organizations, pediatric cancers, while rarer than adult cancers, are increasingly being diagnosed due to better diagnostic technologies and heightened awareness.

Significant research efforts are uncovering novel biomarkers that can enhance early detection and treatment of pediatric cancers. For instance, in June 2024, researchers at the Children's Hospital of Philadelphia (CHOP) announced the discovery of a new immune-based biomarker. This promising biomarker could revolutionize early detection methods, potentially identifying ovarian cancer two to four years before it typically manifests. Such breakthroughs are crucial for improving pediatric oncology treatment outcomes and survival rates. As research continues to yield innovative biomarkers, the market is expanding, with increased investments and focus on developing advanced diagnostic tools. This progress not only supports earlier and more accurate diagnosis but also drives the overall growth of the pediatric cancer biomarkers market.

Additionally, collaboration between academic institutions, research organizations, and pharmaceutical companies drives innovation in the pediatric cancer biomarkers market. Joint research efforts and partnerships facilitate developing and validating new biomarkers through shared expertise and resources. Collaborative initiatives, such as multi-center For instance, in February 2022, Lantern Pharma announced its expansion into additional pediatric cancers through a partnership with The Greehey Children Cancer Research Institute at the University of Texas Health Science Center. studies and public-private partnerships, accelerate the discovery and commercialization of advanced biomarkers. These partnerships enhance the efficiency of research and development processes, contributing to market growth by bringing novel biomarkers to market more rapidly and effectively.

Furthermore, the expansion and improvement of healthcare infrastructure, particularly in emerging markets, are facilitating the growth of the pediatric cancer biomarkers market. As healthcare systems in various regions develop and modernize, there is greater access to advanced diagnostic technologies and biomarker tests. Improved healthcare facilities and services enable the broader implementation of pediatric cancer biomarkers, enhancing diagnostic accuracy and treatment efficacy.

Pediatric Cancer Biomarkers Market Report Highlights:

  • Based on indication, the leukemia segment held the largest share of 40.8% in 2023, owing to the high incidence and need for early detection of this cancer type.
  • Based on biomarker, the CD19, CD20, and CD22 segments held the largest share of 29.7% in 2023, due to their critical roles in diagnosing and targeting hematological cancers. Advances in targeted therapies, such as CAR-T cell therapies, utilize these biomarkers to improve treatment efficacy and patient outcomes. Their growing application in precision medicine is significantly contributing to market expansion.
  • In terms of end use, the hospital segment held the largest share of 40.5% in 2023, driven by increasing investments and government support. Hospitals are adopting advanced biomarker technologies to improve diagnostic accuracy and personalized treatments for pediatric cancers. Government initiatives, such as funding for research and development and incentives for implementing innovative diagnostics, are bolstering market expansion.
  • North America pediatric cancer biomarkers market dominated the overall global market and accounted for the 43.8% revenue share in 2023due to advanced research, increasing cancer incidence, and significant investments in healthcare infrastructure. Enhanced diagnostic technologies and a focus on personalized medicine are driving market expansion, alongside substantial funding and supportive government policies for pediatric cancer research and treatment.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Biomarker
    • 1.2.3. End use
    • 1.2.4. Regional Scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Indication outlook
    • 2.2.2. Biomarker outlook
    • 2.2.3. End use outlook
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Pediatric Cancer Biomarkers Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Incidence of Pediatric Cancer
      • 3.2.1.2. Growing Awareness and Government Initiatives
      • 3.2.1.3. Advancements in Genomics and Proteomics
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Costs of Research and Development
      • 3.2.2.2. Complex Regulatory Requirements
  • 3.3. Pediatric Cancer Biomarkers Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape

Chapter 4. Pediatric Cancer Biomarkers Market: Indication Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Pediatric Cancer Biomarkers Market: Indication Movement Analysis
  • 4.3. Pediatric Cancer Biomarkers Market by Indication Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Leukemia
    • 4.5.1. Leukemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Neuroblastoma
    • 4.6.1. Neuroblastoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. CNS Tumors
    • 4.7.1. CNS Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Lymphoma
    • 4.8.1. Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Pediatric Cancer Biomarkers Market: Biomarker Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Pediatric Cancer Biomarkers Market: Biomarker Movement Analysis
  • 5.3. Pediatric Cancer Biomarkers Market by Biomarker Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Alpha-fetoprotein (AFP)
    • 5.5.1. Alpha-fetoprotein (AFP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Neuron-specific enolase (NSE)
    • 5.6.1. Neuron-specific enolase (NSE) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. CD19, CD20, CD22
    • 5.7.1. CD19, CD20, CD22 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. ALK (anaplastic lymphoma receptor tyrosine kinase gene)
    • 5.8.1. ALK (anaplastic lymphoma receptor tyrosine kinase gene) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Pediatric Cancer Biomarkers Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Pediatric Cancer Biomarkers Market: End Use Movement Analysis
  • 6.3. Pediatric Cancer Biomarkers Market by End Use Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Hospital
    • 6.5.1. Hospital Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Diagnostic Laboratories
    • 6.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Oncology Centers
    • 6.7.1. Oncology Centers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.8. Research Institutions
    • 6.8.1. Research Institutions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Pediatric Cancer Biomarkers Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Market Participant Categorization
  • 8.2. Recent Developments & Impact Analysis by Key Market Participants
  • 8.3. Strategy Mapping
  • 8.4. Key Company Profiles
    • 8.4.1. F. Hoffmann-La Roche Ltd
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Abbott
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Siemens Healthineers
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Thermo Fisher Scientific
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. QIAGEN
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Myriad Genetics
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Beckman Coulter
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Bio-Rad Laboratories
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Agilent Technologies
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. BIOMERIEUX
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. RayBiotech, Inc
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives
    • 8.4.12. Randox Laboratories Ltd.
      • 8.4.12.1. Company overview
      • 8.4.12.2. Financial performance
      • 8.4.12.3. Product benchmarking
      • 8.4.12.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 4 Global pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 5 Global pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America pediatric cancer biomarkers market, by region, 2018 - 2030 (USD Million)
  • Table 7 North America pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 8 North America pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 9 North America pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 10 U.S. pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 11 U.S. pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 12 U.S. pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Canada pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 14 Canada pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 15 Canada pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Mexico pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 17 Mexico pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 18 Mexico pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe pediatric cancer biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Europe pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 22 Europe pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 23 UK pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 24 UK pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 25 UK pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Germany pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 27 Germany pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 28 Germany pediatric cancer biomarkers market, by end use 2018 - 2030 (USD Million)
  • Table 29 France pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 30 France pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 31 France pediatric cancer biomarkers market, by end use 2018 - 2030 (USD Million)
  • Table 32 Italy pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 33 Italy pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 34 Italy pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Spain pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 36 Spain pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 37 Spain pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 38 Denmark pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 39 Denmark pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 40 Denmark pediatric cancer biomarkers market, by end use 2018 - 2030 (USD Million)
  • Table 41 Norway pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 42 Norway pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 43 Norway pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Sweden pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 45 Sweden pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 46 Sweden pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific pediatric cancer biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 51 Japan pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 52 Japan pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 53 Japan pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 54 China pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 55 China pediatric cancer biomarkers market, by biomarker 2018 - 2030 (USD Million)
  • Table 56 China pediatric cancer biomarkers market, by end use 2018 - 2030 (USD Million)
  • Table 57 India pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 58 India pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 59 India pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 60 Australia pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 61 Australia pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 62 Australia pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 63 South Korea pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 64 South Korea pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 65 South Korea pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Thailand pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 67 Thailand pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 68 Thailand pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Latin America pediatric cancer biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 71 Latin America pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 72 Latin America pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 73 Brazil pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 74 Brazil pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 75 Brazil pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 76 Argentina pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 77 Argentina pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 78 Argentina pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 79 Middle East & Africa pediatric cancer biomarkers market, by country, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 83 South Africa pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 84 South Africa pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 85 South Africa pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 89 UAE pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 90 UAE pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 91 UAE pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait pediatric cancer biomarkers market, by indication, 2018 - 2030 (USD Million)
  • Table 93 Kuwait pediatric cancer biomarkers market, by biomarker, 2018 - 2030 (USD Million)
  • Table 94 Kuwait pediatric cancer biomarkers market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Information procurement
  • Fig. 2 Primary research pattern
  • Fig. 3 Market research approaches
  • Fig. 4 Value chain-based sizing & forecasting
  • Fig. 5 Market formulation & validation
  • Fig. 6 Pediatric cancer biomarkers market segmentation
  • Fig. 7 Market driver analysis (current & future impact)
  • Fig. 8 Market restraint analysis (current & future impact)
  • Fig. 9 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 10 Porter's five forces analysis
  • Fig. 11 Pediatric cancer biomarkers market, indication outlook key takeaways (USD Million)
  • Fig. 12 Pediatric cancer biomarkers market: indication movement analysis 2023 & 2030 (USD Million)
  • Fig. 13 Leukemia market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 14 Neuroblastoma market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 15 CNS tumors market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 16 Lymphoma market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 17 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 18 Pediatric cancer biomarkers market, biomarker outlook key takeaways (USD Million)
  • Fig. 19 Pediatric cancer biomarkers market: biomarker movement analysis 2023 & 2030 (USD Million)
  • Fig. 20 Pediatric market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Alpha-fetoprotein (AFP) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Neuron-specific enolase (NSE) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 CD19, CD20, CD22 market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 ALK (anaplastic lymphoma receptor tyrosine kinase gene) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Others market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Pediatric cancer biomarkers market, end use outlook key takeaways (USD Million)
  • Fig. 27 Pediatric cancer biomarkers market: end use movement analysis 2023 & 2030 (USD Million)
  • Fig. 28 Hospital market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Diagnostic laboratories market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Oncology centers market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Research institutions market revenue estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Pediatric cancer biomarkers market: regional key takeaways (USD Million)
  • Fig. 33 Pediatric cancer biomarkers market: regional outlook, 2023 & 2030 (USD Million)
  • Fig. 34 North America pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 US pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Canada pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Mexico pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 UK pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Germany pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 France pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Spain pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Italy pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Norway pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Denmark pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Sweden pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Asia Pacific pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 China pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Japan pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 India pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 South Korea pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Australia pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Thailand pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Latin America pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Brazil pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Argentina pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Middle East and Africa pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 South Africa pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Saudi Arabia pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 UAE pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Kuwait pediatric cancer biomarkers market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 List of key emerging company's/biomarker disruptors/innovators